Kyogoku unyu shoji
9073
BlueMeme
4069
Estore
4304
Visumo
303A
D. Western Therapeutics Institute
4576
(FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | (Q2)Sep 30, 2022 | (Q1)Jun 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | -3.55%39.63B | -1.29%8.51B | -4.71%14.87B | -3.71%8.13B | -3.54%8.13B | -1.05%41.09B | -3.91%8.62B | -0.95%15.6B | 1.33%8.44B | -0.52%8.43B |
Cost of revenue | -4.02%31.48B | -1.03%7.14B | -4.91%10.97B | -4.73%6.78B | -4.90%6.6B | -0.91%32.8B | -5.32%7.21B | -1.12%11.53B | 2.80%7.11B | 0.58%6.94B |
Gross profit | -1.69%8.15B | -2.58%1.37B | -4.16%3.9B | 1.74%1.35B | 2.83%1.53B | -1.58%8.29B | 3.98%1.41B | -0.49%4.07B | -5.92%1.33B | -5.31%1.49B |
Operating expense | -0.02%6.62B | -0.96%1.35B | -0.58%2.37B | 0.98%1.5B | 0.82%1.39B | 2.71%6.62B | 0.33%1.37B | 2.19%2.39B | 3.52%1.48B | 5.20%1.38B |
Staff costs | -1.35%2.54B | -3.63%594.21M | -0.22%697.29M | -0.60%633.42M | -1.12%615.55M | 0.93%2.58B | 0.20%616.59M | -1.58%698.85M | 2.49%637.28M | 3.02%622.55M |
Selling and administrative expenses | 1.27%352.33M | ---- | ---- | ---- | ---- | -7.67%347.92M | ---- | ---- | ---- | ---- |
-Selling and marketing expense | 1.27%352.33M | ---- | ---- | ---- | ---- | -7.67%347.92M | ---- | ---- | ---- | ---- |
Other operating expenses | 0.79%3.72B | 1.22%407.16M | -0.73%1.68B | 2.17%864.04M | 2.42%776.37M | 5.11%3.69B | 8.72%402.25M | 3.84%1.69B | 4.31%845.66M | 7.06%758.06M |
Operating profit | -8.30%1.54B | -54.31%19.61M | -9.24%1.53B | 5.49%-148.19M | 28.31%139.93M | -15.48%1.68B | 756.85%42.91M | -4.05%1.68B | -583.19%-156.8M | -58.18%109.06M |
Net non-operating interest income (expenses) | 13.58%-71.26M | 8.01%-17.58M | 14.96%-19.7M | 9.27%-18.37M | 21.71%-15.6M | 17.05%-82.45M | 20.82%-19.11M | 12.79%-23.17M | 17.97%-20.25M | 17.06%-19.93M |
Non-operating interest income | -9.93%14.99M | -16.03%3.62M | -8.03%3.72M | -7.86%3.81M | -7.51%3.84M | -5.28%16.65M | 2.45%4.31M | -7.60%4.05M | -8.62%4.14M | -6.88%4.15M |
Non-operating interest expense | -12.97%86.25M | -9.48%21.2M | -13.93%23.43M | -9.03%22.18M | -19.26%19.44M | -15.28%99.1M | -17.36%23.42M | -12.05%27.22M | -16.52%24.38M | -15.47%24.08M |
Net investment income | 28.98%93.61M | 7.48%5.64M | 16.86%35.66M | -62.15%4.59M | 93.24%47.73M | -0.52%72.58M | -5.01%5.25M | 2.18%30.51M | 279.17%12.12M | -28.15%24.7M |
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | -107.48%-8.08M | -20M | 8.72M | 0 | -97.04%3.2M | 16,308.56%107.95M | 0 | 0 | 0 | 15,905.12%107.95M |
Income from associates and other participating interests | ||||||||||
Special income (charges) | 30.82%-201.23M | -232.83%-200.55M | 99.30%-1.47M | 1,224.60%4.15M | 82.83%-3.36M | -91.80%-290.89M | 62.04%-60.26M | -6,498.40%-211.4M | 103.15%313K | -242.43%-19.54M |
Less:Restructuring and mergern&acquisition | 474.04%70.94M | --70.94M | --0 | ---- | ---- | --12.36M | --0 | ---- | ---- | ---- |
Less:Other special charges | -54.55%126.58M | 117.88%130.34M | -101.37%-2.73M | -17,984.00%-4.52M | -82.23%3.49M | 74.98%278.53M | -62.42%59.82M | 2,083.76%199.09M | -100.25%-25K | 17,595.50%19.64M |
Less:Write off | --3.71M | -269.28%-733K | 9,444.44%4.21M | 230.21%375K | -35.00%-135K | --0 | 194.34%433K | -100.67%-45K | -712.77%-288K | 99.28%-100K |
Other non-operating income (expenses) | -62.49%77.26M | -60.00%25.53M | -6.62%19.9M | -65.58%9.4M | -76.02%22.43M | 5.26%205.99M | 73.25%63.82M | -27.25%21.31M | -5.94%27.3M | -6.94%93.57M |
Income before tax | -15.51%1.43B | -674.45%-187.35M | 4.71%1.57B | -8.10%-148.44M | -34.30%194.33M | -15.54%1.69B | 122.18%32.61M | -16.20%1.5B | -441.39%-137.31M | -23.12%295.81M |
Income tax | -17.38%567.52M | -277.26%-83.68M | 21.31%186.62M | -4.14%195.33M | -4.54%269.25M | -6.76%686.87M | 144.10%47.21M | -31.28%153.83M | -25.76%203.78M | -18.33%282.05M |
Net income | -14.23%859.94M | -610.37%-103.67M | 2.81%1.38B | -0.79%-343.77M | -644.79%-74.92M | -20.66%1B | 63.52%-14.59M | -14.04%1.34B | -13.75%-341.09M | -65.08%13.75M |
Net income continuous operations | -14.23%859.94M | -610.42%-103.67M | 2.81%1.38B | -0.79%-343.77M | -644.80%-74.92M | -20.66%1B | 63.52%-14.59M | -14.04%1.34B | -13.75%-341.09M | -65.08%13.75M |
Noncontrolling interests | -73.11%1.52M | -151.37%-1.82M | -144.14%-471K | 199.00%1.78M | -27.89%2.03M | 3,066.84%5.64M | 62.93%3.55M | 218.03%1.07M | -47.62%-1.8M | 1,240.89%2.82M |
Net income attributable to the company | -13.90%858.42M | -461.43%-101.85M | 2.92%1.38B | -1.84%-345.55M | -803.85%-76.95M | -21.12%997.01M | 56.99%-18.14M | -14.16%1.34B | -13.61%-339.29M | -72.41%10.93M |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | -13.90%858.42M | -461.43%-101.85M | 2.92%1.38B | -1.84%-345.55M | -803.85%-76.95M | -21.12%997.01M | 56.99%-18.14M | -14.16%1.34B | -13.61%-339.29M | -72.41%10.93M |
Gross dividend payment | ||||||||||
Basic earnings per share | -13.90%606.79 | -461.47%-71.98 | 2.93%977.42 | -1.85%-244.26 | -803.62%-54.39 | -21.11%704.71 | 56.99%-12.82 | -14.16%949.62 | -13.61%-239.82 | -72.40%7.73 |
Diluted earnings per share | -13.90%606.79 | -461.48%-71.9968 | 2.93%977.3953 | -1.85%-244.26 | -803.62%-54.39 | -21.11%704.71 | 56.99%-12.8228 | -14.16%949.6052 | -13.61%-239.82 | -72.40%7.73 |
Dividend per share | 0.00%120 | 0.00%120 | 0 | 0 | 0 | 0.00%120 | 0.00%120 | 0 | 0 | 0 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |